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1. Introduction
Bluetongue (BT), an insect-transmitted, non-contagious
viral disease of domestic and wild ruminants is caused by
bluetongue virus (BTV). The disease is characterized by
inﬂammation of the mucous membranes, congestion,
swelling, hemorrhages and is often accompanied with
high mortality in sheep (Erasmus, 1975; Maclachlan et al.,
2009). Although cattle and goats usually carry the virus for
a certain period of time without showing any apparent
clinical signs of disease, they are capable of transmitting
the virus to other ruminants via biting Culicoides midges.
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A B S T R A C T
Bluetongue (BT) disease, caused by the non-enveloped bluetongue virus (BTV) belonging
to the Reoviridae family, is an economically important disease that affects a wide range of
wild and domestic ruminants. Currently, 26 different serotypes of BTV are recognized in
the world, of which BTV-8 has been found to exhibit one of the most virulent
manifestations of BT disease in livestock. In recent years incursions of BTV-8 in Europe
have resulted in signiﬁcant morbidity and mortality not only in sheep but also in cattle.
The molecular and genetic basis of BTV-8 pathogenesis is not known. To understand the
genetic basis of BTV-8 pathogenicity, we generated reassortant viruses by replacing the
3 most variable genes, S2, S6 and S10 of a recent isolate of BTV-8, in different combinations
into the backbone of an attenuated strain of BTV-1. The growth proﬁles of these
reassortant viruses were then analyzed in two different ovine cell lines derived from
different organs, kidney and thymus. Distinct patterns for each reassortant virus in these
two cell lines were observed. To determine the pathogenicity of these reassortant viruses,
groups of BTV-susceptible sheep were infected with each of these viruses. The data
suggested that the clinical manifestations of these two different serotypes, BTV-1 and BTV-
8, were slightly distinct and BTV-1, when comprising all 3 genome segments of BTV-8,
behaved differently to BTV-1. Our results also suggested that the molecular basis of BT
disease is highly complex.
 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC
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approximately between 408N and 358S (Mellor et al., 2000;
Purse et al., 2005). Until 15 years ago, Europe was
essentially BT-free apart from Cyprus; however, since
1998 at least one of the 26 serotypes of BTV has been active
on the continent every year, mainly in the Mediterranean
basin (Maclachlan and Guthrie, 2010; Mellor et al., 2008;
Purse et al., 2005). In 2006 a highly pathogenic BTV-8
strain emerged for the ﬁrst time in Northern Europe,
spreading very rapidly and affecting thousands of herds.
The same serotype re-emerged in 2007 and 2008, causing
devastating disease not only in sheep but also in cattle with
high morbidity and mortality (Elbers et al., 2008a, 2008b;
Wilson and Mellor, 2009). Studies involving molecular
epidemiology have also shown that the most severe
disease in northern European sheep and cattle was caused
by BTV-8 (Dal Pozzo et al., 2013; Martinelle et al., 2013;
Purse et al., 2005). The phenotypic differences between
BTV-8 compared with less virulent strains suggested that
genetic background may be partly responsible. However,
the mechanism of pathogenicity is still very poorly
understood.
BTV is a member of the Orbivirus genus within the
Reoviridae family. Like other members of the family, BTV has
a genome of 10 segmented double-stranded RNA (segments
S1–S10) that are enclosed within two capsids. While the
inner core is made up of 5 highly conserved proteins (VP1,
VP3, VP4, VP6 and VP7), the outer capsid consists of two
variable proteins, VP2 (receptor-binding protein and sero-
type determinant) and VP5 (membrane penetration pro-
tein). In addition, BTV also encodes for 4 non-structural
proteins (NS1–NS4), of which NS3 encoded by S10 is more
variable than NS1 and NS2. NS3 is shown to be involved in
virus trafﬁcking and release from the infected host (Beaton
et al., 2002; Celma and Roy, 2009). Recently it has been
shown that NS3 is also involved in the regulation of the
induction of interferon type 1 (Chauveau et al., 2013),
suggesting a role in the innate immune response.
In this study, we designed reassortant viruses between
BTV-8 and BTV-1 to establish the genetic basis of BTV
pathogenicity. The rationale for designing reassortant
viruses was based on the two most variable proteins of
the outer capsid (VP2 and VP5) and the non-structural
protein NS3, which is the most variable within BTV NS
proteins. Reassortant viruses were generated using a
reverse genetics (RG) system replacing these three RNA
segments (S2, S6 and S10) of the low virulent strain, BTV-1,
with that of highly virulent BTV-8, either singly or in
combinations. The phenotypic characteristics of the
disease caused by these reassortant viruses were analyzed
by infection of sheep. Our results suggested that all three
proteins together are involved in the disease outcome and
that the molecular basis of BTV pathogenicity is highly
complex.
2. Methods
2.1. Cells and viruses
BSR cells (BHK-21 subclone) were maintained in
Dulbecco modiﬁed eagle medium (DMEM, Sigma–Aldrich)
supplemented with 5% (v/v) fetal bovine serum (FBS,
Invitrogen). PT and SFT-R cells (ovine-derived kidney and
thymus cells respectively, Collection of Cell Lines in
Veterinary Medicine, Friedrich-Loefﬂer-Institut, Insel
Riems, Germany) were maintained in minimum essential
medium eagle (MEM, Sigma–Aldrich) supplemented with
10% (v/v) FBS.
BTV-1 (South African strain) and BTV-8 (Ardennes
isolate) viral stocks were generated by infection of BSR
cells and kept at 4 8C until use.
2.2. Recovery of reassortant BTV-1/BTV-8 viruses
Segments S2 (VP2), S6 (VP5) and S10 (NS3) (GenBank
accession numbers: KJ872780–KJ872782) of BTV-8 were
obtained using a sequence-independent cloning system
as previously described (Boyce et al., 2008; Maan et al.,
2007; Matsuo et al., 2011). Brieﬂy, dsRNAs from puriﬁed
core particles were ligated to a self-annealing primer
before RT-PCR ampliﬁcation using a speciﬁc primer. Each
cDNA ampliﬁed from segments S2, S6 and S10 of BTV-8
was cloned into pUC19 and fully sequenced (Source
Bioscience) before insertion of the T7 promoter at the
50 end and insertion of a unique restriction enzyme
site that generates the correct end of the segment at
the 30 end.
For synthesis of uncapped T7 transcripts for segments
S2, S6 and S10, RiboMAX Large-Scale RNA Production
System T7 (Promega) or TranscriptAid T7 High Yield
Transcription Kit (Thermo Scientiﬁc) kits were used
according to manufacturer’s instructions. Reassortant
viruses between BTV-1 and BTV-8 were recovered from
conﬂuent monolayers of BSR cells after transfection with a
full set of BTV T7 transcripts as described before (Boyce
et al., 2008). Individual plaques were picked, ampliﬁed and
virus stocks were kept at 4 8C.
2.3. Virus growth kinetics and characterization
The genomic dsRNA proﬁle was analyzed for each
reassortant. Monolayers of BSR cells were infected with
reassortant or parental viruses and upon complete
cytopathic effect, infected cells were harvested. The
genomic dsRNA was puriﬁed with Tri reagent (Sigma)
using standard methods. The parental origin of segments
S2, S6 and S10 was determined by differential mobility in
non-denaturing PAGE or by sequencing.
For virus growth study, monolayers of PT and SFT-R
cells were synchronously infected at a multiplicity of
infection (MOI) of 1 and samples were collected at 0, 12,
24 and 48 h (hours) post-infection (p.i.). Cells and
supernatant were harvested, subjected to two freeze/thaw
cycles and the total titer was determined by plaque assay
in triplicate and expressed as plaque formation units per
ml (PFU/ml) or by tissue culture infective dose 50 (TCID50).
The mean, standard deviation and the p values were also
determined by Excel (Microsoft). Viral protein expression
was determined by Western blot (WB) using speciﬁc
antibodies against structural VP5, VP7 and non-structural
NS3 proteins. As loading control, an antibody against
b-actin (Sigma) was used. Each blotting experiment was
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ntitated by ImageJ software.
 Pathogenicity studies
Forty-six sheep (East Frisian breed) were segregated in
ups of 4 animals and subcutaneously injected with
ental BTV-1 (South African strain), BTV-8 (Ardennes
ate) or one of the reassortant viruses at 1  107 PFU/
mal. Control groups received only saline buffer. Whole
od samples were taken at regular intervals before and
r infection. For three weeks, a clinical score was
igned daily to each sheep based on a range of clinical
s. These included body temperature, feed intake,
tude, and lameness, appearance of conjunctiva, scleral
od vessels and cornea, appearance of skin and mucous
mbranes of the nose and mouth, redness and
orrhaging, nasal and ocular discharge, salivation,
piratory rate and sounds, as well as edema of the
gue, face, ears, periorbital and submandibular regions.
ending on severity, up to four points were awarded per
egory. All animal procedures were in compliance with
opean ethical regulations, i.e. directives 91/628, 92/65
 86/609/EEG, regarding the protection of vertebrate
mals used for experimental and/or scientiﬁc purposes.
A mixed-design analysis of the variance model (imple-
nted in R, http://www.r-project.org/) was used to test
signiﬁcant differences in clinical scores between
ups. P values from post hoc pairwise comparisons
re adjusted for multiplicity by the Bonferroni method.
 Viral load
To determine virus replication in animal hosts, RNA was
racted from blood samples at different time points with
 NucleoSpin 96 virus core kit (Macherey-Nagel) and
lyzed by real-time RT-PCR as described previously
ussaint et al., 2007) using a LightCycler 480II (Roche
gnostics). A NS1 (S5) RNA standard was used for
olute quantiﬁcation.
 Immunological tests
The presence of antibodies against BTV VP7 was
asured by ELISA. Serum samples were analyzed by a
ble-recognition BTV antibody ELISA (PrioCHECK BTV
 Prionics GmbH). For neutralization tests, serum
ples were tested against parental BTV-1 and BTV-8
ses and the neutralization titer was determined as the
hest dilution able to neutralize 100 TCID50 of virus in
 of replicate wells.
esults
 Recovery and characterization of reassortant BTV-1 and
-8 viruses
Initially BTV-8 (Ardennes isolate) (Le Gal et al., 2008)
ct-copy segments S2, S6 and S10, encoding VP2, VP5
 NS3 respectively, were cloned using a sequence-
ependent method (Boyce et al., 2008; Maan et al., 2007).
Subsequently, after ensuring the accuracy of the clones by
sequencing, a T7 promoter and a speciﬁc restriction
enzyme site were introduced by PCR and transcripts were
generated using the fully digested plasmids as templates.
For virus recovery, BSR cells were transfected with ssRNAs
S2, S6 and S10 of BTV-8 in different combinations together
with the remaining ssRNAs (either 7 or 8 segments) of BTV-
1 (Boyce et al., 2008). Following incubation, reassortant
viruses were recovered as described previously (Boyce
et al., 2008) and assessment of the plaque morphology
established that the recovered BTV1/8VP2.5 (with seg-
ments S2 and S6 of BTV-8) and BTV1/8VP2.5.NS3 (with
segments S2, S6 and S10 of BTV-8) reassortant viruses had
plaque formation similar to the parental viruses (data not
shown).
Puriﬁcation of the genomic dsRNAs from cells infected
with independent plaques of BTV1/8VP2.5 and BTV1/
8VP2.5.NS3 and their subsequent analysis on a non-
denaturing polyacrylamide gel conﬁrmed that the recov-
ered reassortant viruses had the expected dsRNA genome
patterns that were equivalent to the parental origin of the
segments (Fig. 1A, left panel). In addition, RT-PCR and
sequencing also validated the authenticity of the segments
that could not be assessed by their mobility in non-
denaturing polyacrylamide gels.
Since pathogenicity of BT disease is more pronounced in
sheep, ovine cells were evaluated for growth kinetics and
protein expression at different times p.i. For this purpose,
ﬁrst an ovine cell line (PT) derived from kidney was
infected at MOI of 1 with either wild-type BTV-1 or BTV-8
or reassortant virus BTV-1/8VP2.5 or BTV-1/8VP2.5.NS3.
Virus growth kinetics was monitored by plaque assay
(Fig. 1A, right panel) of samples taken at 0, 12, 24 and 48 h
p.i. Although both reassortant viruses BTV1/8VP2.5 and
BTV1/8VP2.5.NS3 consisted of a BTV-1 backbone, the
growth characteristics of only the triple reassortant were
different to that of BTV-1. Reassortant virus BTV1/8VP2.5
exhibited a similar proﬁle to BTV-1, with only a slight
difference at 12 h (p < 0.05) but not at (p > 0.05) either
24 or 48 h p.i. In contrast, the triple reassortant BTV-1/
8VP2.5.NS3 virus titer at 12 h p.i. was signiﬁcantly
different from BTV-1 (p < 0.05) but not from BTV-8 at
the same time point (p > 0.05). However, growth of this
virus at later times (24 and 48 h p.i.) exhibited a somewhat
different (p < 0.05) proﬁle in comparison to both parental
viruses, BTV-1 and BTV-8, albeit closer to BTV-8.
Since triple reassortant virus BTV1/8VP2.5.NS3
appeared to have a different growth proﬁle to that of
BTV-1, the growth patterns of these two viruses were
further analyzed using an alternate ovine cell line, ovine
thymus SFT-R cells. As VP2, VP5 and NS3 in the triple
reassortant virus BTV1/8VP2.5.NS3 were taken from BTV-
8, the latter was also included as a control. Analysis of the
growth proﬁles of the three viruses in SFT-R cells (Fig. 1B,
left panel) exhibited that the virus titers of the reassortant
virus, BTV-1 and BTV-8 at 12 h p.i. were similar and there
was no statistically signiﬁcant difference (p > 0.05) be-
tween them. Although virus titers of reassortant and BTV-8
plateaued by 24 h p.i., the only virus that still continued to
grow at the later time points was the BTV-1. Further,
Western blot analysis of viral protein expression, using
C.C. Celma et al. / Veterinary Microbiology 174 (2014) 139–147142antibodies for NS3, VP5 and a major structural protein VP7
(Fig. 1B, right panel), revealed that all three viruses
expressed these proteins as early as 12 h p.i. Since the
virus titers of the triple reassortant virus, BTV-1 and BTV-8
were not statistically signiﬁcant from each other at 12 h
p.i., the protein expression for all three viruses was
measured at 24 and 48 h p.i. Further, densitometric
analysis of protein expression at each time point indicated
that the increase in expression of VP7 and VP5, but not NS3,
was similar to BTV-8; while NS3 was more similar to BTV-1
(results not shown). Altogether, this suggested that
exchanging S2, S6 and S10 segments of BTV-1 with that
of BTV-8 resulted in a reassortant virus that was more
similar to BTV-8 than BTV-1. In addition, the effect of the
reassortment was more pronounced in the thymus-
derived (SFT-R) than in the kidney (PT) cells.
3.2. Pathogenicity in sheep infected with BTV reassortant
viruses
Since in tissue culture the triple reassortant virus BTV1/
8VP2.5.NS3 behaved more similarly to BTV-8 and BTV-1/
8VP2.5 to BTV-1, experiments were designed to analyze
the pathogenicity of these reassortant viruses in animal
hosts. For this purpose, four groups containing four sheep
in each group were infected with BTV-1 or BTV-8 or BTV1/
8VP2.5 or BTV1/8VP2.5.NS3. Two animals injected with
saline buffer were used as the control group. The
pathogenicity of each virus infection was analyzed by
clinical observation of the animals in all groups. A clinical
score was assigned daily to each sheep based on a range of
clinical symptoms as described in Section 2. Depending on
severity, up to four points were awarded per category.
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Fig. 1. Characterization of reassortant BTV-1/BTV-8 viruses. (A) Left panel, genomic proﬁle of reassortant viruses generated by RG. DsRNA was extracted
from cells infected with either BTV-1, BTV-8, BTV1/8VP2.5.NS3 or BTV1/8VP2.5 and analyzed in a non-denaturing polyacrylamide gel. Arrows indicate
reassortant segments S2, S6 or S10 of BTV-8 in each generated virus. Right panel, virus growth proﬁle in the ovine kidney-derived PT cell line. Cells were
infected with parental BTV-1 or BTV-8, or reassortant BTV1/8VP2.5.NS3 or BTV1/8VP2.5 and samples were harvested at the indicated times. Titers at each
time point were determined in triplicate by plaque assay, expressed as virus growth in plaque formation units per ml (PFU/ml) and plotted in logarithmic
scale. Error bars indicate standard deviation. Asterisk and hashtag indicates the signiﬁcance (p < 0.05) of the difference in titers of BTV1/8VP2.5.NS3 or
BTV1/8VP2.5 at 12, 24 and 48 h p.i. to WT BTV-1 (*) or BTV-8 (#). (B) Characterization of BTV1/8VP2.5.NS3 in ovine thymus-derived SFT-R cells. Left panel,
virus growth. Cells were infected with BTV1/8VP2.5.NS3 or parental BTV-1 or BTV-8 and processed as indicated in (A). The p values were designated the
same way as in (A). Right panel, protein expression proﬁle from cells infected with BTV1/8VP2.5.NS3 at the indicated time points. Viral proteins were
detected by Western blot using speciﬁc antibodies against VP5, VP7 or NS3. As loading control, an antibody against cellular actin was used. Protein proﬁle
from cells infected with BTV-1 and BTV-8 was used as controls.
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sented a slightly early onset of the highest clinical score
pared to BTV1/8VP2.5 or BTV-1 (Fig. 2A). As the same
tern was also observed for BTV-8 with a maximum
ical score at 6 days p.i., this data suggested that the NS3
ht inﬂuence virus pathogenicity and might play an
ortant role in the onset of BT disease. Although the
ical scores in all four infection groups were different
 the control group, the observed differences between
 infection groups were not statistically signiﬁcant.
Subsequently, viremia in these infected animals was
mated by analyzing the whole blood samples that were
en before virus inoculation and on days 1 to 7, 9, 11, 14,
 19, and 21 p.i. using real-time RT-PCR (Toussaint et al.,
7). Animals infected with the reassortant viruses
wed an increase in the number of NS1 gene copies
r the ﬁrst week after infection (Fig. 2B) similar to BTV-1
 BTV-8 viruses, indicating that these viruses can
licate as efﬁciently as parental viruses in an animal
t. In comparison, samples from control sheep were free
TV RNA. (Fig. 2B, control). While productive infection
asured by detecting the presence of antibodies against
, the group-speciﬁc antigen, by ELISA, also demon-
ted that all animals in the infection groups had
oconverted by day 7 after inoculation, no BTV antibody
response was detected in any sample from the negative
control sheep (data not shown). In addition, the serum
neutralization response tested in samples taken at 21 days
p.i. conﬁrmed that animals infected with the reassortant
viruses BTV1/8VP2.5.NS3 and BTV1/8VP2.5 showed a
strong neutralization response against BTV-8 but not
BTV-1 (Table 1). In comparison, animals infected with BTV-
1 presented a response only against the same serotype.
Overall these data indicated that the reassortant viruses
are able to replicate in animals and they also generate a
strong immune response similar to that of the parental
strains. Since the sheep infected with the reassortant
BTV1/8VP2.5.NS3 showed a clinical score that was
comparable to that of BTV-8, it was hypothesized that
NS3 might be playing an important role in the pathoge-
nicity of BT disease.
3.3. Importance of NS3 in bluetongue disease in sheep
To further determine the importance of NS3 in
pathogenicity, we generated a reassortant virus in which
S10 of BTV-1 was exchanged with S10 of BTV-8, BTV1/
8NS3 by RG system (Fig. 3A). In addition, two other
reassortants BTV1/8VP2.NS3 and BTV1/8VP5.NS3 were
generated to determine the contribution of each segment
in the context of NS3. Further, a sequence comparison
between the segment S10 of BTV-1 and BTV-8 showed that
only 12 residues in the NS3 sequence are different between
these two serotypes, of which 5 are located at the putative
extracellular domain of NS3. To determine if these
differences play any role in pathogenicity, we introduced
the substitutions L149I/S153K/A154T/I156V/Q158S in the BTV-
1 NS3 sequence and generated a mutant virus BTV1/
NS3IKTVS that expressed an NS3 protein containing an
extracellular domain similar to that of BTV-8. Each
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2. Clinical manifestation and virus replication in sheep infected with
sortant BTV1/BTV-8 viruses. (A) Animals were inoculated with
sortants BTV1/8VP2.5.NS3, BTV1/8VP2.5 or parental BTV-1 or BTV-8.
cted animals were examined daily. Attitude, body temperature and
r clinical signs were recorded and scored as outlined in the text.
ns and standard deviation were calculated for each group. (B)
als were inoculated with virus as above and blood samples for
ction of NS1 gene by real-time RT-PCR were taken at the indicated
 points. As control, a group of animals injected with saline buffer was
uded in the study.
Table 1
Serum neutralization titer in animals infected with BTV1/8VP2.5.NS3,
BTV1/8VP2.5 or parental BTV-1 or BTV-8.
Infection group BTV-1 (dilution)a BTV-8 (dilution)a
BTV-1 (4 animals) 1/640 Negative
1/240 Negative
1/240 Negative
1/480 Negative
BTV-8 (4 animals) Negative 1/480
Negative 1/240
Negative 1/240
Negative 1/320
BTV1/8VP2.5 (4 animals) Negative 1/240
Negative 1/240
Negative 1/120
Negative 1/120
BTV1/8VP2.5.NS3 (4 animals) Negative 1/480
Negative 1/320
Negative 1/480
Negative 1/120
PBS (2 animals) Negative Negative
Negative Negative
Negative indicates no detectable neutralizing activity in a 1/10 dilution.
a Neutralizing activity in serum samples from sheep 21 days post-
infection with reassortant or parental virus was determined as the highest
dilution that neutralized 100 TCID50 virus in 50% of replicate wells.
C.C. Celma et al. / Veterinary Microbiology 174 (2014) 139–147144reassortant virus was grown in BSR cells and stocks were
stored at 4 8C. Although all viruses yielded titers between
1.5  107 and 4.6  107 PFU/ml, BTV1/8VP5.NS3 yielded
consistently lower titers (1  106) than the other
reassortant viruses.
Further, the growth of each virus was examined in
ovine SFT-R cells. Interestingly, both BTV1/8NS3 and BTV1/
NS3IKTVS single reassortant viruses behaved like BTV-1,
not BTV-8. The other two dual reassortant viruses,
BTV1/8VP2.NS3 and BTV1/8VP5.NS3, behaved as an
intermediate between two parental viruses as shown in
Fig. 3B, suggesting that NS3 might be acting in concert with
each of the outer capsid proteins.
For pathogenicity studies, animals were divided into
six infection groups and a control group with four sheep in
each group. Sheep in the infection groups were inoculated
with BTV-1 or BTV-8 or one of four different reassortant
BTV-1/BTV-8 viruses. Animals were clinically scored daily
and blood samples were taken before and at days 1–11, 14,
17, and 21 days after infection. All the generated viruses
(reassortants and mutant) were able to replicate in sheep,
as real-time RT-PCR demonstrated an increasing amount
of S6 RNA in blood samples over time (data not shown).
When the animals were clinically scored, similar to the
parental BTV-1, a delay in pathogenicity was observed for
the virus BTV1/8VP2.NS3 with a maximum score at 8 days
p.i. (Fig. 3B). The reassortants BTV1/8VP5.NS3, BTV1/
8NS3, mutant BTV1/NS3IKTVS and BTV-8 reached a
maximum score at seven days p.i. (Fig. 4A and B). The
clinical scores in all infection groups were signiﬁcantly
different from the control group; however, the observed
differences between the infection groups were not
statistically signiﬁcant.
4. Discussion
BTV serotypes, BTV-1 and BTV-8, have displayed a
marked ability to spread and severe virulence has been
reported during European outbreaks in domestic rumi-
nants, sheep being among the most severely affected
livestock species (Allepuz et al., 2010; Elbers et al., 2008b).
Detailed investigations in sheep to elucidate the patho-
genic mechanisms of BTV-1 under experimental condi-
tions are scarce (Hamblin et al., 1998; Perez de Diego et al.,
2011). In comparison, infections carried out with BTV-8 in
sheep have been accompanied by a signiﬁcant variation in
results (Darpel et al., 2007; Elbers et al., 2008c; Worwa
et al., 2010). Recently, two studies have also reported a
comparative study involving pathogenicity of BTV-1 and -8
in sheep and cattle (Dal Pozzo et al., 2013; Sanchez-Cordon
et al., 2013). This is the ﬁrst study to investigate how the
difference in the clinical manifestations between BTV-1
and BTV-8 is inﬂuenced by the genetic origin of the virus.
Since there is some evidence in previous reports regarding
the involvement of VP2 and VP5, the two most exposed
viral capsid proteins as determinants of virus virulence
(DeMaula et al., 2000; Huismans and Howell, 1973), we
have explored whether variations in pathogenicity are
likely to be associated with the two most variable BTV
genomic segments, S2 and S6 that encode VP2 and VP5
respectively. In addition, as S10, the gene encoding for NS3
has also been found to be the most variable amongst the
segments encoding for the non-structural proteins in BTV
infected cells, this protein was also hypothesized to play a
potentially important role in BTV pathogenesis. Interest-
ingly, in BTV infected cells it has also been demonstrated
that the interaction of VP2 and VP5 with NS3 has an
important role in virus assembly and trafﬁcking (Beaton
et al., 2002; Bhattacharya and Roy, 2008; Celma and Roy,
2009, 2011; Wirblich et al., 2006).
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BTV1/8VP2.NS3, BTV1/8VP5.NS3 and BTV1/8VP2.5 or single BTV1/8NS3
and BTV1/NS3IKTVS viruses and samples were harvested at 48 h p.i. Total
titers were determined by TCID50 and expressed as percentage of BTV-8
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C.C. Celma et al. / Veterinary Microbiology 174 (2014) 139–147 145For this purpose, the BTV RG system was utilized to
erate reassortant viruses that consisted of a backbone
TV-1, with VP2, VP5 and NS3 of BTV-8 in ﬁve different
binations (BTV1/8VP2.5, BTV1/8VP2.5.NS3, BTV1/
2.NS3, BTV1/8VP5.NS3 and BTV1/8NS3). In each of
 reassortants the equivalent genome segment of BTV-1
s replaced by BTV-8. This is the ﬁrst time that
ssortant viruses generated by RG technology have been
ed in an animal host.
In order to investigate the inﬂuence of tissue speciﬁcity
the growth pattern of the reassortant viruses and to
pare it with the two parental strains of BTV-1 and BTV-
heep kidney (PT) and thymus (SFT-R) cell lines were
cted with the respective viruses. Since our primary
ective was to assess the importance of the VP2, VP5 and
 in BTV pathogenesis, growth curves and virus protein
duction of reassortant virus BTV1/8VP2.5.NS3 were
essed in the two different ovine cell types. Our results
wed that both wild-type viruses as well as the
ssortant viruses had different growth proﬁles in each
 line, indicating that there may be a tissue speciﬁcity
ted to a particular strain that may play a role in virus
hogenicity. In addition, our results also revealed that
 growth pattern of BTV1/8VP2.5 and not BTV1/
2.5.NS3 was similar to that of BTV-1 in the ovine
ney cell line. Experiments undertaken with BTV1/
2.5.NS3, BTV-1 and BTV-8 in ovine thymus cell lines
demonstrated a more pronounced similarity in growth
proﬁle between BTV1/8VP2.5.NS3 and BTV-8 but not BTV-
1. This conﬁrmed that substituting all 3 segments, S2, S6
and S10 of BTV-1, with that of BTV-8 resulted in a
reassortant virus that was more similar in behavior to BTV-
8 than BTV-1. Since the effect was more pronounced in the
ovine thymus SFT-R cell line, this also validated that in cell
culture systems the origin of the cultured cells does play a
signiﬁcant role in determining virus growth character-
istics. Hence, on the basis of these studies it was postulated
that the growth proﬁle of a particular BTV strain was
dependent on VP2, VP5 and NS3.
Consequently, experiments designed to analyze the
pathogenicity of BTV1/8VP2.5 and BTV1/8VP2.5.NS3 in
sheep revealed that parental BTV-8 and reassortant BTV1/
8VP2.5.NS3 triggered an earlier onset of clinical disease
symptoms than parental BTV-1 and reassortant BTV1/
8VP2.5. Interestingly, our results are in direct contrast to
another recent investigation undertaken in sheep that
have demonstrated that BTV-1 is more pathogenic than
BTV-8. The difference in pathogenicity of BTV-1 and BTV-8
between our current study and that undertaken by
Sanchez-Cordon et al. (2013) can be attributed to the fact
that the BTV-1 strain used to recover our reassortant
viruses was a tissue culture adapted strain obtained from
South Africa. Subsequently, RT-PCR on blood samples
procured from infected sheep and serum neutralization
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4. Pathogenicity of reassortants BTV1/8VP2.NS3, BTV1/8VP5.NS3, BTV1/8NS3 or mutant BTV1/NS3IKTVS viruses. (A, B) Clinical signs were recorded
heep infected with BTV1/8VP2.NS3 (A), BTV1/8VP5.NS3 (A), BTV1/8NS3 (B) or mutant BTV1/NS3IKTVS (B) viruses using the same scoring described in
2. Parental BTV-1 and BTV-8 viruses were also included as control (same set of data was plotted in each graph).
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8VP2.5.NS3 were able to replicate in animals and that
they also were able to generate a strong immune response
similar to that of the parental strains. Since sheep infected
with reassortant BTV1/8VP2.5.NS3 showed similar clinical
scores to that of BTV-8, it led us to further hypothesize that
of the 3 proteins, VP2, VP5 and NS3, the non-structural
protein NS3 might be an important contributing factor for
the development of BT disease. Hence, three more
reassortant viruses were generated by RG system in which
S10 of BTV-8 was either present singly (BTV1/8NS3) or in a
combination with either BTV-8 VP2 (BTV1/8VP2.NS3) or
VP5 (BTV1/8VP5.NS3). Sequence comparison of S10
belonging to BTV-1 and BTV-8 highlighted the presence
of only 12 amino acid residues that were variable between
the two serotypes. Since a cluster containing 5 of these
variable residues was located in the putative extracellular
domain of NS3, a mutant virus was generated (BTV1/
NS3IKTVS) that only contained amino acid substitutions
(L149I/S153K/A154T/I156V/Q158S) in this region of NS3.
Consequently, this domain of BTV-1 NS3 became identical
to the extracellular domain of BTV-8. When the reassortant
and the mutant virus were inoculated in sheep, real-time
RT-PCR of blood samples demonstrated that all the newly
generated viruses and the two parental strains could
replicate in sheep. Although pathogenicity analysis of the
reassortant viruses suggested that BTV1/8VP2.NS3 be-
haved similarly to BTV-1, while the other two reassortant
viruses (BTV1/8NS3 and BTV1/8VP5.NS3) and the mutant
virus BTV1/NS3IKTVS were similar to BTV-8, the overall
clinical scores were not signiﬁcantly different. Based on
our result it was hypothesized that the two outer capsid
proteins (VP2 and VP5) and the non-structural protein NS3
are all acting in concert with each other and are to a certain
extent responsible for the pathogenicity of a particular
strain. Interestingly, earlier reports have demonstrated
that the interaction of NS3 with the two outer capsid
proteins and cytoplasmic proteins have important con-
sequences for both virus assembly and trafﬁcking in
infected cells (Beaton et al., 2002; Bhattacharya and Roy,
2008; Celma and Roy, 2009, 2011; Wirblich et al., 2006).
Since mutant virus BTV1/NS3IKTVS, consisting of an
extracellular loop region identical to that of BTV-8 NS3,
did not show a statistical signiﬁcant difference in virus
pathogenicity when compared to the two parental strains,
it can be concluded that the loop region of NS3 or its
interaction with various cellular partners does not have a
signiﬁcant contribution to BT pathogenesis. Although the
role of the remaining seven highly conserved BTV genomic
segments cannot be negated, further work on this aspect is
beyond the remit of this paper. Clinical experiments
undertaken with BTV-1 and BTV-8 showed a different
proﬁle in two different sets of experiments (Figs. 2 and 4).
Since these two animal experiments were conducted over
one year apart, it is possible that in spite of every effort that
was made to keep conditions consistent between experi-
ments, some variations occurred. However, it is unlikely
that the small variation between experiments invalidates
the ﬁndings made within each of the experiments. The role
of NS3 in regulating interferon response has recently been
investigate interferon responses of the triple reassortant
virus versus the two wild-type viruses in the animal.
However, these will require a series of experiments and
detailed analysis that are beyond the remit of this study.
5. Conclusion
The clinical disease and pathogenicity of BTV is a very
complex process and cannot be explained by the presence
or absence of only one genome segment or its protein
product. Much more work needs to be undertaken to
clearly understand the genetic basis of BT pathogenesis
and to our knowledge, this is the ﬁrst report in this
particular research area.
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